Efficacy and Safety of Pasireotide Long Acting Release (LAR) in Combination With Weekly Pegvisomant in Previously Controlled Acromegaly Patients on Combination Treatment of Long-Acting Somatostatin Analogues and Weekly Pegvisomant (PAPE)

NCT02668172 Phase 4 UNKNOWN

The objective of this study is to assess the efficacy of Pasireotide Long Acting Release (LAR) alone and in combination with weekly Pegvisomant (PEGV) in acromegaIy patients previously controlled with combination treatment of long-acting Somatostatin analogs (LA-SSAs) and PEGV.

Details

Lead sponsor	Erasmus Medical Center
Phase	Phase 4
Status	UNKNOWN
Enrolment	60
Start date	2015-08
Completion	2017-06

Conditions

• Acromegaly

Interventions

• Pasireotide LAR 60 mg
• Pegvisomant

Primary outcomes

• The proportion of patients with normalized IGF1 levels at 24 weeks in the pasireotide LAR monotherapy group and in the pasireotide LAR combined with pegvisomant group — 24 weeks

Countries

Netherlands